2025-06-12-Jefferies-海波飞（HYPR）_停止覆盖_8页_113kb

报告摘要

Report Date: June 13, 2025

Jefferies announces discontinuation of equity coverage for Hyperfine with a HOLD rating.
Price target: $0.75, a +1% revision from the prior trading day's close of $0.74.

Hyperfine is a medical device company specializing in portable MRI systems (e.g., Swoop).
Base incorporated in 2014, located in Guilford, Connecticut, with a market capitalization of $56.1M. Swoop offers point-of-care neuroimaging with advantages in portability and image quality.

Market Cap: $56.1M, Ticker: HYPR.
EPS Projections (2025E): -$0.10 for Q1, -$0.11 for Q2, -$0.10 for Q3, and -$0.09 for Q4.
Negative revenue and EPS growth expected for 2025 and 2026 compared to prior years.

Strengths: Swoop is differentiated for neuroimaging with benefits like portability and ease of use, supported by positive time savings and improved usability from physician surveys.
Challenges: Early commercialization issues include low awareness, lack of clinical data, and unpredictable selling cycles, leading to potential consensus misses.
Scenarios:
- Base Case: Revenues, margins, and cash flow aligned with current projections.
- Upside: Possibility of expanding clinical indications and benefiting from new Alzheimer's-related scans, targeting $1.00 PT.
- Downside: Missed sales targets, poor cash burn, or failure to secure product approvals, with PT at $0.50.

Factors: Quarterly financial performance, cash burn runway, regulatory delays, interest rate volatility, hospital capital spending trends, or unexpected takeout offers could impact the rating and price target.

PT of $0.75 is above current cash value. Valuation is based on methods including DCF and EV/Sales, with an emphasis on market conditions and growth potential.

Catalysts: Positive quarterly results, new product approvals, and increased awareness.
ESG: Company addresses environmental and diversity matters, though no specific targets are set.